766515-33-7

Basic information

• Product Name: 3-Cyano-2-hydroxy-5-iodopyridine
• Synonyms: 3-Cyano-2-hydroxy-5-iodopyridine;2-Hydroxy-5-iodonicotinonitrile;5-Iodo-2-oxo-1,2-dihydropyridine-3-carbonitrile;1,2-Dihydro-5-iodo-2-oxo-3-pyridinecarbonitrile
• CAS NO: 766515-33-7
• Molecular Formula: C₆H₃IN₂O
• Molecular Weight: 246.01
• Product Categories: alcohol|cyanide| alkyl Iodine
• Mol File: 766515-33-7.mol

Chemical Properties

• Boiling Point: 423.534 °C at 760 mmHg
• Flash Point: 209.946 °C
• Appearance: /
• Density: 2.239 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.724
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-Cyano-2-hydroxy-5-iodopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cyano-2-hydroxy-5-iodopyridine(766515-33-7)
• EPA Substance Registry System: 3-Cyano-2-hydroxy-5-iodopyridine(766515-33-7)

Safety Data

• Hazardous Substances Data: 766515-33-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Cyano-2-hydroxy-5-iodopyridine serves as a valuable building block in organic synthesis, contributing to the creation of a wide range of chemical compounds. Its unique functional groups allow for various chemical reactions, making it a useful intermediate in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Cyano-2-hydroxy-5-iodopyridine is utilized as a key component in the development of new drugs. Its presence in molecules can potentially enhance their biological activity, making it a promising candidate for the design of novel therapeutic agents.
Used in Antimicrobial Applications:
3-Cyano-2-hydroxy-5-iodopyridine has been studied for its antimicrobial properties, demonstrating potential as an agent against various microorganisms. Its ability to inhibit microbial growth makes it a candidate for use in antimicrobial formulations and treatments.
Used in Antitumor Applications:
3-Cyano-2-hydroxy-5-iodopyridine has also shown promise in antitumor research, indicating its potential to be developed as an anticancer agent. Its ability to target and inhibit tumor growth could lead to the development of new cancer therapies, offering hope for improved treatment options in the future.

InChI:InChI=1/C6H3IN2O/c7-5-1-4(2-8)6(10)9-3-5/h1,3H,(H,9,10)

Upstream product

• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 20577-27-9 2-hydroxy-3-cyanopyridine 

Downstream Products

• 766515-34-8 2-chloro-5-iodopyridine-3-carbonitrile 
• 766515-35-9 1-methyl-3-amino-5-iodo-1H-pyrazolo[3,4-b]pyridine 
• 766515-42-8 1-methyl-3-amino-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-45-1 1-methyl-3-iodo-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-40-6 1-methyl-3-(2,2-dimethyl-propionamido)-5-phenyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-39-3 (E)-1-methyl-3-(2,2-dimethyl-propionamido)-5-styryl-1H-pyrazolo[3,4-b]pyridine 
• 766515-38-2 1-methyl-3-(2,2-dimethyl-propionamido)-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 1392150-08-1 5-[(3,5-difluorophenyl)thio]-1H-pyrazolo[3,4-b]pyrazin-3-amine 
• 1392151-65-3 N-(5-(3,5-difluorophenylthio)-1-(4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido) benzoyl)-1H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide 
• 1392151-64-2 N-(5-((3,5-difluorophenyl)thio)-1H-pyrazolo[3,4-b]pyrazin-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide 
• 1392151-76-6 1-(5-((3,5-difluorophenyl)thio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)thiourea 
• 1392151-89-1 5-(3,5-difluorophenyl sulfinyl)-1H-pyrazolo[3,4-b]pyrazin-3-amine 
• 1392151-92-6 5-[(3,5-difluorophenyl)sulfonyl]-1H-pyrazolo[3,4-b]pyrazin-3-amine 

Relevant articles and documents

Original synthesis of radiolabeling precursors for batch and on resin one-step/late-stage radiofluorination of peptides

Radiolabeling of peptides with fluorine-18 is hurdled by their chemical sensitivity and complicated processes. Original triflyl-pyridine intermediates afforded ammonium precursors that were radiolabeled at low temperature. From that study, a generic tag h

Derivatives of azaindoles or diazaindoles for treating pain

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK

The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

Synthesis of 3,5-difunctionalized 1-methyl-1H-pyrazolo[3,4-b]pyridines involving palladium-mediated coupling reactions

Indirect iodination of 2-chloro-nicotinonitrile gave 2-chloro-5- iodonicotinonitrile, which was cyclized with methylhydrazine to lead to 3-amino-5-iodopyrazolo[3,4-b]pyridine. Position 3 was then protected by pivaloyl group and the resulting 5-iodo-3-pivaloylaminopyrazolo[3,4-b]pyridine was engaged in palladium-promoted coupling reactions with various reagents to give 3-pivaloylamino-5-substituted compounds. Deprotection and iododediazoniation followed by cross-coupling reactions in position 3 afforded novel unsymmetrical 3,5-disubstituted pyrazolo[3,4-b]pyridine species.